A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

  1. Paz-Ares, L.
  2. Kunka, R.
  3. DeMaria, D.
  4. Cassidy, J.
  5. Alden, M.
  6. Beranek, P.
  7. Kaye, S.
  8. Littlefield, D.
  9. Reilly, D.
  10. Depee, S.
  11. Wissel, P.
  12. Twelves, C.
  13. O'Dwyer, P.
Aldizkaria:
British Journal of Cancer

ISSN: 0007-0920

Argitalpen urtea: 1998

Alea: 78

Zenbakia: 10

Orrialdeak: 1329-1336

Mota: Artikulua

DOI: 10.1038/BJC.1998.679 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus